Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With PembrolizumabFrancesco Jacopo Romano, Ferdinando Riccardi, I Giacobbe et al.|Cancer Diagnosis & Prognosis|2022Cited by 28
Stocky/Packed Pancreas: A Case of Focal Drug-Induced Acute Pancreatitis Mimicking CancerMarco Di Serafino, Luigia Romano, Roberto Ronza et al.|Tomography|2022Cited by 5
Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathyMaria Giuseppa Vitale, Ferdinando Riccardi, Anna Crispo et al.|Frontiers in Pharmacology|2022Cited by 2
Folinic acid in colorectal cancer: esquire or fellow knight? Real-world results from a mono institutional, retrospective studyFrancesco Jacopo Romano, Ferdinando Riccardi, Carmela Barbato et al.|Oncotarget|2021Cited by 1
13P High neutrophils-to-lymphocyte ratio (NLR) predicts poor survival of high-PD-L1-expressing metastatic non-small cell lung carcinoma patients undergoing first-line immunotherapy with pembrolizumabFrancesco Jacopo Romano, Ferdinando Riccardi, Carmela Barbato et al.|Annals of Oncology|2021Cited by 0